Differences in immunogenicity to zoster recombinant vaccine in IMID patients undergoing treatment with non-selective or selective JAK-i

Our study highlights impaired immune responses to the recombinant herpes zoster vaccine in IMID patients treated with JAK-is. These patients showed significantly reduced humoral and cellular responses, suggesting lower protection against VZV reactivation. While anti-TNF/MTX-treated patients had mildly reduced responses compared with controls, their immunogenicity was relatively preserved. In contrast, JAK-i-treated patients had markedly lower antibody titers and T cell responses. Notably, this impairment was more pronounced with non-selective JAK-is than with selective JAK1 inhibitors, underscoring differences within the JAK-i class.